Ricimed® (Antidote #1)

About Fabentech

Founded in 2007, Fabentech is a private, clinical-stage biotech focused on biodefense and pandemic preparedness. Its core asset is the FabShield® platform for generating polyclonal antibody fragment therapies against lethal biological agents. The company has a diversified pipeline targeting toxins and viruses, with one product (Ricimed®) approved, another in Phase 2 for COVID-19, and several earlier-stage programs backed by European and French defense agencies. Fabentech operates as a specialized contractor for government and public health preparedness markets.

Therapeutic Areas